Phase 3 Readout~month

Phase 3 Topline: A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Eff

Indication
Depression; Bipolar I Disorder

Other upcoming events for ABBV

Phase 3 ReadoutPhase 3 Topline: A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Te
Phase 3 ReadoutPhase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy an
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of
Phase 3 ReadoutPhase 3 Topline: A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and S

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Eff — ABBV Phase 3 Readout | BioSniper